A Phase 2 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Matching placebo in Major Depressive Disorder, sponsored by Shire. Completed at 33 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder (MDD) as measured by the Global Executive Composite (GEC) T-score of the Behavioral Rating Inventory of Executive Functioning - Adult Version (BRIEF-A).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
SPD489
Drug: SPD489 (Lisdexamfetamine dimesylate)
Placebo
Drug: Matching placebo
Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
Also known as: Vyvanse
oral, once daily
Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)
BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and week 9
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Baseline and week 9
Change From Baseline in BRIEF-A T-scores at Week 9, LOCF
BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
Time frame: Baseline and week 9
Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint
This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores \< 70 indicate likely deficit and impairment, and scores \> 110 indicate high function and capacity. Higher scores are better.
Time frame: Baseline and up to 9 weeks/Endpoint
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Baseline
Percent of Participants With CGI-S at up to 9 Weeks/Endpoint
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Up to 9 weeks/Endpoint
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Week 9
Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint
The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity.
Time frame: Baseline and up to 9 weeks/Endpoint
Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.
Time frame: Baseline and week 9
Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.
Time frame: Baseline and week 9
Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health).
Time frame: Baseline and week 9
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint
The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction.
Time frame: Baseline and up to 9 weeks/Endpoint
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: Baseline and week 11
Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF
The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety.
Time frame: Baseline and week 9
Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9
The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies.
Time frame: Baseline and week 9
| Milestone | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Started | 71 | 72 |
| Completed | 60 | 59 |
| Not completed | 11 | 13 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Non-compliance | 1 | 2 |
| Withdrew: Out-of-window visits | 0 | 1 |
BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF) | -21.2 ± 1.67 | -13.2 ± 1.66 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF) | -5.0 ± 0.66 | -3.1 ± 0.66 |
BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.
| T-scores | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Behavioral recognition index | -17.4 ± 1.51 | -12.3 ± 1.50 |
| Inhibit subscale | -13.5 ± 1.26 | -9.3 ± 1.25 |
| Shift subscale | -16.2 ± 1.51 | -10.6 ± 1.50 |
| Emotional control subscale | -13.8 ± 1.48 | -10.1 ± 1.47 |
| Self-monitor subscale | -13.8 ± 1.36 | -10.7 ± 1.35 |
| Metacognition index | -21.1 ± 1.67 | -12.2 ± 1.66 |
| Initiate subscale | -19.4 ± 1.57 | -10.8 ± 1.56 |
| Working memory subscale | -20.1 ± 1.65 | -11.0 ± 1.64 |
| Plan/Organize subscale | -18.7 ± 1.58 | -11.3 ± 1.57 |
| Task monitor subscale | -16.8 ± 1.63 | -11.9 ± 1.62 |
| Organization of materials subscale | -15.2 ± 1.49 | -8.2 ± 1.48 |
This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores \< 70 indicate likely deficit and impairment, and scores \> 110 indicate high function and capacity. Higher scores are better.
| Response scores | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Complex information speed processing index | 8.7 ± 10.13 | 3.7 ± 9.02 |
| Executive function index | 11.0 ± 14.80 | 6.0 ± 14.43 |
| Neurocognitive index | 11.5 ± 17.14 | 2.5 ± 13.74 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| percentage of participants | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Normal, not at all ill | 0.0 | 2.8 |
| Borderline mentally ill | 7.0 | 8.3 |
| Mildly ill | 42.3 | 36.1 |
| Moderately ill | 45.1 | 48.6 |
| Markedly ill | 4.2 | 4.2 |
| Severely ill | 1.4 | 0.0 |
| Among the most extremely ill | 0.0 | 0.0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| percentage of participants | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Normal, not at all ill | 21.7 | 15.9 |
| Borderline mentally ill | 40.6 | 23.2 |
| Mildly ill | 20.3 | 24.6 |
| Moderately ill | 14.5 | 34.8 |
| Markedly ill | 2.9 | 1.4 |
| Severely ill | 0.0 | 0.0 |
| Among the most extremely ill | 0.0 | 0.0 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF | 60.6 | 38.9 |
The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint | -20.4 ± 2.24 | -15.9 ± 2.32 |
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF | 2.5 ± 4.61 | 2.4 ± 5.34 |
This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF | 2.7 ± 8.47 | 1.6 ± 5.60 |
The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health).
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Aggregate physical | -0.10 ± 0.461 | -0.23 ± 0.473 |
| Aggregate mental | 0.69 ± 0.987 | 0.63 ± 0.807 |
The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Physical health activities | 17.9 ± 20.03 | 8.2 ± 16.82 |
| Overall life satisfaction | 12.1 ± 25.37 | 9.1 ± 22.27 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11 | -9.4 ± 14.43 | -5.9 ± 10.86 |
The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF | -4.4 ± 5.81 | -3.8 ± 5.43 |
The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9 | -0.1 ± 0.40 | 0.0 ± 0.13 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate (LDX) | — | 2/71 (2.8%) | 56/71 (78.9%) |
| Placebo | — | 4/72 (5.6%) | 53/72 (73.6%) |
| Event | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Loss of consciousnessNervous system disorders | 1/71 | 0/72 |
| Suicidal ideationPsychiatric disorders | 1/71 | 0/72 |
| GastroenteritisInfections and infestations | 0/71 | 1/72 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/71 | 1/72 |
| SalmonellosisInfections and infestations | 0/71 | 1/72 |
| Pelvic inflammatory diseaseInfections and infestations | 0/71 | 1/72 |
| Event | Lisdexamfetamine Dimesylate (LDX) | Placebo |
|---|---|---|
| Decreased appetiteInvestigations | 16/71 | 3/72 |
| HeadacheNervous system disorders | 16/71 | 11/72 |
| Dry mouthGastrointestinal disorders | 11/71 | 6/72 |
| InsomniaPsychiatric disorders | 10/71 | 2/72 |
| IrritabilityGeneral disorders | 9/71 | 5/72 |
| Urinary tract infectionInfections and infestations | 7/71 | 3/72 |
| Upper respiratory tract infectionInfections and infestations | 6/71 | 4/72 |
| AnxietyPsychiatric disorders | 6/71 | 4/72 |
| NauseaGastrointestinal disorders | 5/71 | 4/72 |
| FatigueGeneral disorders | 4/71 | 4/72 |
| Age, Continuous(years) | Lisdexamfetamine Dimesylate (LDX) | Placebo | Total |
|---|---|---|---|
| Mean | 41.9 ± 9.79 | 39.5 ± 10.59 | 40.7 ± 10.23 |
| Age, Customized(Participants) | Lisdexamfetamine Dimesylate (LDX) | Placebo | Total |
|---|---|---|---|
| 18 to 39 years | 28 | 34 | 62 |
| 40 to 55 years | 43 | 38 | 81 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate (LDX) | Placebo | Total |
|---|---|---|---|
| Female | 51 | 48 | 99 |
| Male | 20 | 24 | 44 |
| Region of Enrollment(Participants) | Lisdexamfetamine Dimesylate (LDX) | Placebo | Total |
|---|---|---|---|
| United States | 71 | 72 | 143 |
Ran from Oct 2009 to primary completion in Apr 2011, 17 months.
Results were first posted in Apr 2012, 11 months after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine